- Home
- MNR vs AUPH Comparison
MNR vs AUPH Comparison
Compare MNR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNR | AUPH |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MNR | AUPH |
|---|---|---|
| Price | $12.42 | $16.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.00 | $17.25 |
| AVG Volume (30 Days) | 379.4K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.29% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,175,390,000.00 | $283,055,000.00 |
| Revenue This Year | $34.60 | $17.54 |
| Revenue Next Year | $2.35 | $15.74 |
| P/E Ratio | ★ N/A | $65.72 |
| Revenue Growth | ★ 21.22 | 20.38 |
| 52 Week Low | $10.46 | $7.29 |
| 52 Week High | $15.58 | $16.88 |
Technical Indicators
Market Signals| Indicator | MNR | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 60.55 |
| Support Level | $11.95 | $14.60 |
| Resistance Level | $12.86 | $16.88 |
| Average True Range (ATR) | 0.37 | 0.52 |
| MACD | -0.13 | 0.07 |
| Stochastic Oscillator | 17.21 | 86.17 |
Price Performance
Historical ComparisonAbout MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas; the San Juan Basin region of New Mexico and Colorado; and the Permian Basin region of West Texas. The company is organized and managed as a single reportable segment, which is the exploration and production of oil, natural gas and NGLs (E&P Segment).
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.